Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

17.7%

59 terminated/withdrawn out of 333 trials

Success Rate

80.5%

-6.0% vs industry average

Late-Stage Pipeline

48%

160 trials in Phase 3/4

Results Transparency

42%

102 of 244 completed trials have results

Key Signals

5 recruiting102 with results51 terminated8 withdrawn

Enrollment Performance

Analytics

Phase 3

114(36.0%)

Phase 1

100(31.5%)

Phase 4

46(14.5%)

Phase 2

43(13.6%)

N/A

12(3.8%)

Early Phase 1

2(0.6%)

317Total

Phase 3(114)

Phase 1(100)

Phase 4(46)

Phase 2(43)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (333)

Showing 20 of 333 trials

NCT02411695Phase 1Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Role: collaborator

NCT06706622Phase 3Active Not Recruiting

A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

Role: lead

NCT06323928Phase 2Active Not Recruiting

A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

Role: lead

NCT06557850Phase 1Active Not Recruiting

A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease

Role: lead

NCT05164172Phase 3Recruiting

A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

Role: lead

NCT05104476Phase 2Active Not Recruiting

A Study of Lu AF82422 in Participants With Multiple System Atrophy

Role: lead

NCT07035197Completed

Facilitators and Barriers to Eptinezumab Administration in Thailand

Role: collaborator

NCT05897320Phase 3Recruiting

A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Role: lead

NCT04965675Phase 3Recruiting

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

Role: lead

NCT05669950Phase 1Recruiting

A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

Role: lead

NCT06701526Phase 4Active Not Recruiting

A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

Role: lead

NCT04291859Phase 1Completed

Lu AF28996 in Participants With Parkinson's Disease (PD)

Role: lead

NCT06471829Phase 2Recruiting

A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

Role: lead

NCT03238326Phase 3Completed

Safety and Tolerability of Open-Label Flexible-dose Brexpiprazole as Maintenance Treatment in Adolescents With Schizophrenia

Role: collaborator

NCT05452239Phase 4Completed

A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

Role: lead

NCT04921384Phase 3Completed

Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

Role: lead

NCT05064371Phase 3Completed

Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

Role: lead

NCT00308893Phase 4Completed

BDNF Gene Polymorphism and Antidepressants Treatment

Role: collaborator

NCT05453058Active Not Recruiting

Observational Study in Multiple System Atrophy

Role: lead

NCT04653688Not ApplicableCompleted

Markers of Disease Progression and Gait Within the Parkinsonian Population

Role: collaborator